Available datapackage for study 'A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers'

The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B
and to compare the PK profile with that of BIIB033-A in healthy volunteers. Secondary
objectives are: To assess the safety and tolerability of BIIB033-A and BIIB033-B; To assess
the secondary PK parameters of BIIB033-A and BIIB033-B; To assess the immunogenicity of
BIIB033-A and BIIB033-B.